en · de · es · fr · pt
cjc-1295-notes.peptides9002.com › Wiki › Albumin Binding And Duration Of Action — Research Overview

Albumin Binding And Duration Of Action — Research Overview

By Editorial Desk · published 2026-02-24 · last reviewed 2026-04-08 · Wiki

MOD GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-04-08. Where a claim depends on a specific study, the study is described rather than over-claimed.

Albumin Binding and Duration of Action

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Cjc-1295 at a glance

PropertyValueNotes
Duration with linkerSeveral daysReported in early human work
Duration without linkerTens of minutesShort plasma residence
Albumin attachment siteCysteine-34Covalent maleimide reaction
Primary receptorPituitary GHRH receptorStimulates growth hormone release
Downstream markerInsulin-like growth factor 1Indirect measure of activity

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Related pages on this site

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Reference notes

The Mkhedrioni (Georgian: მხედრიონი, romanized: mkhedrioni) was a Georgian nationalist paramilitary organisation founded in 1989 by Jaba Ioseliani. It emerged during Georgia's transition to independence from the Soviet Union and played a major role in the Georgian Civil War and the War in Abkhazia. The Mkhedrioni was notorious for intimidation and criminal activities, including extortion, smuggling, robbery, and operating illegal roadblocks. It was banned by President Zviad Gamsakhurdia in 1991, regained influence after participating in the 1991–92 Georgian coup d'état that overthrew Gamsakhurdia, and was outlawed again in 1995 after the authorities accused Ioseliani and others of involvement in the attempted assassination of President Eduard Shevardnadze. After failing to secure registration to contest elections under its own name, it reconstituted itself as the Union of Patriots political party, which was also refused registration.

== Modern hue rendering == True Tyrian purple, like most high-chroma pigments, cannot be accurately rendered on a standard RGB computer monitor. Ancient reports are also not entirely consistent, but these swatches give a rough indication of the likely range in which it appeared: _________ _________ The lower one is the sRGB colour #990024, intended for viewing on an output device with a gamma of 2.2. It is a representation of RHS colour code 66A, which has been equated to "Tyrian red", a term which is often used as a synonym for Tyrian purple.

Partially hydrogenated vegetable oils were an increasingly significant part of the human diet for about 100 years, especially after 1950 as processed food rose in popularity. Animal-based fats were once the only trans fats consumed, but by far the largest amount of trans fat consumed today is created by the processed food industry as a side effect of partially hydrogenating unsaturated plant fats (generally vegetable oils). These partially hydrogenated fats have displaced natural solid fats and liquid oils in many areas, the most notable ones being in the fast food, snack food, fried food, and baked goods industries. Up to 45% of the total fat in those foods containing human-made trans fats formed by partially hydrogenating plant fats may be trans fat. An analysis of some industrialized foods in 2006 found up to 30% "trans fats" in artificial shortening, 10% in breads and cake products, 8% in cookies and crackers, 4% in salty snacks, 7% in cake frostings and sweets, and 26% in margarine and other processed spreads. Another 2010 analysis however found only 0.2% of trans fats in margarine and other processed spreads. Foods containing higher amounts of trans fat are associated with fast food restaurants. They are consumed in greater quantities by people who lack access to a diet consisting of fewer partially hydrogenated fats, or who often consume fast food. A diet high in trans fats can contribute to obesity, high blood pressure, and higher risk for heart disease. Trans fat is also implicated in Type 2 diabetes.

=== Early years === Sidney Fox was the son of Jacob Fox, a wig-maker, and Louise Berman, a Ukrainian immigrant. Fox married Raia Joffe Fox and they had three sons: Lawrence, Ronald, and Thomas. All three of his sons became scientists. His family was Jewish. Fox obtained a Bachelor of Arts degree from University of California, Los Angeles in Chemistry. He went on to earn a Ph.D. from California Institute of Technology in 1940 and did his postdoctoral work at the Linus Pauling Laboratory where he grew close with Linus Pauling.

Sources: en.wikipedia.org

Reference notes

=== Outer membrane vesicle === Outer membrane vesicles (OMVs) are naturally immunogenic and can be manipulated to produce potent vaccines. The best known OMV vaccines are those developed for serotype B meningococcal disease.

Once the food is in the digestive cavity, gland cells in the gastroderm release enzymes that reduce the prey to slurry, usually within a few hours. This circulates through the digestive cavity and, in colonial cnidarians, through the connecting tunnels, so that gastroderm cells can absorb the nutrients. Absorption may take a few hours, and digestion within the cells may take a few days. The circulation of nutrients is driven by water currents produced by cilia in the gastroderm or by muscular movements or both, so that nutrients reach all parts of the digestive cavity. Nutrients reach the outer cell layer by diffusion or, for animals or zooids such as medusae which have thick mesogleas, are transported by mobile cells in the mesoglea. Indigestible remains of prey are expelled through the mouth. The main waste product of cells' internal processes is ammonia, which is removed by the external and internal water currents.

== Development == Half-Life: Opposing Force was announced by developer Gearbox Software on April 15, 1999. In their press release, founder Randy Pitchford stated that "our number one goal is to preserve the integrity of Half-Life and provide new experiences that expand upon the sensation of the original". The name Opposing Force has a double meaning, referring both to the fact that the player is one of the enemies in the original game, as well as to Newton's third law of motion. In a later interview, Pitchford stated that he believed that Valve offered Gearbox the chance to make a Half-Life expansion was from a wish "to focus on their future titles". In addition, Pitchford commented that Valve and Gearbox had agreed not to "severely modify" the game engine used by Half-Life and Opposing Force as it "risks breaking all of the wonderful work" that the game's custom content community was creating. Substantial information on Opposing Force's development direction, as well as new locations, characters and story were revealed at the 1999 Electronic Entertainment Expo convention. The official website for Opposing Force, hosted by publisher Sierra Studios, was put online in July 1999. Opposing Force was developed in 8 months by a team of more than 15 people. Over the course of development, Gearbox acquired various outside talent to assist in designing some aspects. In June 1999, Gearbox announced that level designer Richard Gray would be assisting in developing the multiplayer aspects.

"Vitellogenin, juvenile hormone, insulin signaling, and queen honey bee longevity". Proceedings of the National Academy of Sciences. 104 (17): 7128–33. Bibcode:2007PNAS..104.7128C. doi:10.1073/pnas.0701909104. PMC 1852330. PMID 17438290.

Bickley and Sundridge (17,766) Bromley Common and Holwood (18,781) Bromley Town (15,400) Hayes and Coney Hall (15,908) Plaistow (13,478) Shortlands and Park Langley (16,207) The 2021 U.K. census reported the entire borough of Bromley overall had a population 329,991.

Sources: en.wikipedia.org

Frequently asked questions

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Does the modification change how the peptide signals?

The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.

Are human half-life figures well established?

Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.

Why is mass spectrometry used alongside chromatography?

Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.

Network